Open AccessClinical and hematological data to group different chronic kidney disease patients: A practical approach to establish different groups of patients
Author(s) -
Péterle Vinícius B.,
Souza Jéssica de O.,
Busato Fernanda de O.,
Eutrópio Frederico J.,
Costa Gisele de A. P.,
Olivieri David N.,
Tadokoro Carlos E.
Publication year - 2018
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.22377
Subject(s) - kidney disease , medicine , pathological , renal function , disease , dialysis , incidence (geometry) , inflammation , kidney , gastroenterology , immunology , optics , physics
Background Chronic kidney disease ( CKD ) is the convergent point of several pathological processes, and its evolution is insidious and characterized by a progressive and irreversible loss of kidney function. This impaired function induces the accumulation of uremic toxins and individuals with terminal CKD often have altered physiological responses, including a persistent state of immuno‐suppression and development of diseases. A better characterization and stratification of these patients with CKD in different immuno‐compromised groups would contribute to more effective and personalized treatments. The focus of this study was to use two parameters to stratify patients with CKD into four separate groups that are representative of different immunological status. Methods Patients with CKD were chosen randomly and stratified into four separate groups according to the period of time receiving dialysis treatment and leukocyte blood counts. The amount of apoptotic CD 4 T cells were measured in each group of patients, and clinical/hematological parameters were correlated by multivariate analysis with each group. Results Observations reveal that one of the four groups of patients with CKD (group 3) had more apoptotic CD 4 T cells than the other group; this group also had an increased malnutrition inflammation score ( MIS ), an elevated Kt/V, and a higher incidence of smoking. Conclusion A simple two‐parameter‐based stratification strategy could be used to design effective immunological therapies that differentiate the degrees of immuno‐suppression across groups of patients with CKD .